A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the tokyo or connaught strain for nonmuscle invasive bladder cancer

Journal of Urology

Volumn 190, Issue 1, 2013, Pages 50-54

  Sengiku, Atsushi ^a   Ito, Masaaki ^a   Miyazaki, Yu ^a   Sawazaki, Harutake ^a   Takahashi, Takeshi ^a   Ogura, Keiji ^a  

^a OTSU RED CROSS HOSPITAL   (Japan)

Author keywords

BCG Connaught; BCG vaccine; Japan; treatment outcome; urinary bladder neoplasms

Indexed keywords

BACILLUS CALMETTE GUERIN CONNAUGHT STRAIN VACCINE; BACILLUS CALMETTE GUERIN TOKYO 172 STRAIN VACCINE; BCG VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BCG VACCINATION; BURNING SENSATION; CANCER SURVIVAL; CARCINOMA IN SITU; CLINICAL TRIAL; CYSTITIS; DRUG EFFICACY; DRUG FEVER; FEMALE; FOLLOW UP; HEMATURIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MICTURITION; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SAFETY; PROSPECTIVE STUDIES; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84878822363     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2013.01.084     Document Type: Article

References (18)

1. K.H. Kurth, R. Sylvester Prognostic factors in non-muscle-invasive bladder tumors: I Clinical prognostic factors: a review of the experience of the EORTC Genito-Urinary Group II. Biologic prognostic markers Eur Urol 6 suppl. 2007 789
2. R.J. Sylvester, A.P. van der Meijden, D.L. Lamm Intravesical bacillus Calmette-Guérin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials J Urol 168 2002 1964
3. M.F. Sarosdy, D.L. Lamm Long-term results of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer J Urol 142 1989 719
4. M.S. Cookson, M.F. Sarosdy Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guérin therapy J Urol 148 1992 797
5. D. Margel, R. Tal, S. Golan Long-term follow-up of patients with stage T1 high grade transitional cell carcinoma managed by bacillus Calmette- Guérin immunotherapy Urology 69 2007 78
6. T. Okamura, K. Tozawa, Y. Yamada Clinicopathological evaluation of repeated courses of intravesical bacillus Calmette-Guérin instillation for preventing the recurrence of initially resistant superficial bladder cancers J Urol 156 1996 967
7. T. Gårdmark, S. Jahnson, R. Wahlquist Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer BJU Int 99 2007 817
8. D.L. Lamm, B.A. Blumenstein, J.D. Crissman Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study J Urol 163 2000 1124
9. M.R. Lagranderie, A.M. Balazuc, E. Deriaud Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains Infect Immunol 64 1996 1
10. M.A. Behr, P.M. Small A historical and molecular phylogeny of BCG strains Vaccine 17 1999 915
11. H. Akaza, S. Hinotsu, Y. Aso Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder Four-year results. The Bladder Cancer BCG Study Group Cancer 75 1995 552
12. H.W. Herr, A. Morales History of bacillus Calmette-Guérin and bladder cancer: an immunotherapy success story J Urol 179 2008 53
13. M. Babjuk, W. Oosterlinck, R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997
14. H. Akaza, K. Koiso, S. Ozono A clinical study of PMCJ-9 (Bacillus Calmette-Guérin Connaught strain) treatment of superficial bladder cancer and carcinoma in situ of the bladder Jpn J Clin Oncol 33 2003 382
15. N. Ikeda, I. Honda, I. Yano Bacillus Calmette-Guerin Tokyo172 substrain for superficial bladder cancer: characterization and antitumor effect J Urol 173 2005 1507
16. Japanese Urological Association, Japanese Society of Pathology and Japan Radiological Society General Rule for Clinical and Pathological Studies on Renal Pelvis, Ureter and Bladder Cancer 2011 Kanehara Tokyo
17. F. Saint, J. Irani, J.J. Patard Tolerability of bacille Calmette-Guérin maintenance therapy for superficial bladder cancer Urology 57 2001 883
18. Rentsch CA, Birkhauser F, Studer UE, et al. A randomized phase III study comparing the efficacy of bacillus Calmette-Guérin strain Tice versus Connaught for immunotherapy of non-muscle invasive bladder cancer. Presented at annual meeting of American Association for Cancer Research, Chicago, Illinois, March 31-April 4, 2012, abstract 2691.